Skip to main content
Premium Trial:

Request an Annual Quote

Personalis Establishes UK Subsidiary

NEW YORK (GenomeWeb News) – Personalis has formed a UK subsidiary, Personalis UK Limited, to serve its customers in Europe.

Menlo Park, Calif.-based Personalis provides researchers and clinicians human DNA sequencing and interpretation services.

The company also announced that it has appointed Mark Dronsfield to the post of director of European sales. He joins the company from RainDance Technologies, where he served as head of commercial operations in Europe, and has previously held commercial operations positions in Europe for Illumina, Affymetrix, and Life Technologies.

Personalis plans to initially build out its commercial team in the UK, but will also build services infrastructure as the customers' needs require.

"Given the expanding research and clinical demands for large-scale exome and genome analysis, we felt it was important to augment our presence in the European markets," said Personalis CEO John West in a statement. "We wanted to be prepared to build infrastructure on both the commercial and operational sides, so we are best able to address the needs of researchers and clinicians."

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.